CEOs, Senior Executives Highlight Expansions at the DCAT Member Company Announcement Forum

CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week.

CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week.

By Patricia Van Arnum, Editorial Director, DCAT, [email protected] 

CEO and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT) and the premier event for the global bio/pharmaceutical business ecosystem. Companies reported the latest in expansion plans across the bio/pharmaceutical value chain: from drug substances (small-molecules and biologics) to drug products (solid dosage and injectable product forms) and packaging. In all, 20 companies took to the podium to make their announcements. The program kicked off DCAT Week on Monday March 23, 2026. 

Details of each company’s announcement can be found below. 

Recent Feature Articles

What Is New and Upcoming in Small-Molecule Drugs?

By
Which small-molecule drugs are making the mark in 2026 in new drug approvals or in recently or soon-to-be launched drugs? DCAT Value Chain Insights takes an inside look.

US Gov’t Makes Next Move to Onshore Mfg of Generics

By
The White House is moving to identify new and unused domestic, US-based, and near-shore production capacity to meet a goal of localizing manufacturing of essential medicines.

How Autonomous Will the Supply Chain Be?

By
A recent analysis by Gartner projects low uptake of AI for autonomous supply-chain planning decisions by 2030, but AI does factor into the workflows of the top 25 supply-chain organizations, according to the firm’s annual rankings, but how?

Novo at a Crossroads: Will Its Strategic Plan Deliver?

By
Novo’s CEO Mike Doustdar laid out a strategic growth plan for the company, which included a plan to launch more than five multi-blockbusters by 2030 and expand beyond its obesity and diabetes franchise. Will he and the company be able to deliver?